文献速递胸部肿瘤消化系统肿瘤泌尿男性生殖肿瘤

液体活检基因组数据与影像组学在结肠癌、胰腺癌、肺癌和前列腺癌患者中的相关性

The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients.
PubMed 文献 · Eur J Cancer · 2025-07-08

本研究基于STING试验(NCT04932525)的418例患者,回顾性分析液体活检与CT影像组学整合预测实体瘤基因组改变的能力,采用XGBoost逻辑分类器建模。胰腺癌KRAS突变预测AUC达0.97,肺癌BRAF突变AUC为0.79,结肠癌BRAF突变AUC为0.76,前列腺癌AR突变AUC仅0.63。作者认为该整合方法可行,但需进一步前瞻性验证。

要点

  • 胰腺癌KRAS突变影像组学预测模型AUC=0.97,判别能力最佳。
  • 肺癌EGFR突变AUC=0.74,BRAF突变AUC=0.79;结肠癌BRAF突变AUC=0.76。
  • 前列腺癌AR突变判别能力有限(AUC=0.63)。

核心结论

  • 本研究提示整合影像组学与液体活检用于实体瘤无创基因组分析具有可行性,在患者分层和个体化肿瘤诊疗方面展现出显著潜力。
  • 作者指出,尽管结果 promising,仍需进一步前瞻性验证以提升模型的可推广性。

研究设计与样本

  • 回顾性研究,纳入来自STING试验(NCT04932525)的418例患者,所有患者均接受液体活检和CT影像检查。
  • 使用XGBoost逻辑分类器开发预测模型,并进行统计分析以比较不同分子亚型间的肿瘤体积、病灶数量和受累器官。
  • 采用曲线下面积(AUC)值和交叉验证技术评估模型性能。

主要发现

  • 影像组学模型在预测基因组改变方面表现出中等至良好性能。
  • 胰腺癌中KRAS突变识别效果最佳(AUC=0.97),肺癌(AUC=0.66)和结肠癌(AUC=0.64)中判别能力中等。
  • 肺癌中EGFR突变检测AUC为0.74;BRAF突变在肺癌(AUC=0.79)和结肠癌(AUC=0.76)中均显示出良好判别能力。
  • 前列腺癌中AR突变在影像组学预测模型中判别能力有限(AUC=0.63)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需进一步前瞻性验证以提升模型的可推广性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: With the advances in artificial intelligence (AI) and precision medicine, radiomics has emerged as a promising tool in the field of oncology. Radiogenomics integrates radiomics with genomic data, potentially offering a non-invasive method for identifying biomarkers relevant to cancer therapy. Liquid biopsy (LB) has further revolutionized cancer diagnostics by detecting circulating tumor DNA (ctDNA), enabling real-time molecular profiling. This study explores the integration of radiomics and LB to predict genomic alterations in solid tumors, including lung, colon, pancreatic, and prostate cancers. METHODS: A retrospective study was conducted on 418 patients from the STING trial (NCT04932525), all of whom underwent both LB and CT imaging. Predictive models were developed using an XGBoost logistic classifier, with statistical analysis performed to compare tumor volumes, lesion counts, and affected organs across molecular subtypes. Performance was evaluated using area under the curve (AUC) values and cross-validation techniques. RESULTS: Radiomic models demonstrated moderate-to-good performance in predicting genomic alterations. KRAS mutations were best identified in pancreatic cancer (AUC=0.97), while moderate discrimination was noted in lung (AUC=0.66) and colon cancer (AUC=0.64). EGFR mutations in lung cancer were detected with an AUC of 0.74, while BRAF mutations showed good discriminatory ability in both lung (AUC=0.79) and colon cancer (AUC=0.76). In the radiomics predictive model, AR mutations in prostate cancer showed limited discrimination (AUC = 0.63). CONCLUSION: This study highlights the feasibility of integrating radiomics and LB for non-invasive genomic profiling in solid tumors, demonstrating significant potential in patient stratification and personalized oncology care. While promising, further prospective validation is required to enhance the generalizability of these models.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Italiano A, Gautier O, Dupont J, et al. The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients. Eur J Cancer. 2025. PMID: 40645032. doi:10.1016/j.ejca.2025.115609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。